C
CTI Biopharma Corp
F:CEPS
CTI Biopharma Corp
F:CEPS
Price:
28
EUR
Market Closed
Market Cap:
€3.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
CTI Biopharma Corp
F:CEPS
|
US |
|
M
|
Mitra International Resources Tbk PT
IDX:MIRA
|
ID |
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
CN |
|
Sichuan Em Technology Co Ltd
SSE:601208
|
CN |
|
First Bancorp
NYSE:FBP
|
PR |
|
S
|
Sfinks Polska SA
WSE:SFS
|
PL |
|
U
|
Urano Energy Corp
CNSX:UE
|
CA |
|
O
|
Oriental Hotels Ltd
NSE:ORIENTHOT
|
IN |
|
C
|
CTOS Digital Bhd
KLSE:CTOS
|
MY |
|
Finexia Financial Group Ltd
ASX:FNX
|
AU |
|
Frasers Logistics & Commercial Trust
SGX:BUOU
|
SG |
|
L
|
Link Mobility Group Holding ASA
OSE:LINK
|
NO |
|
W
|
Wooree E&L Co Ltd
KOSDAQ:153490
|
KR |
|
Anjani Portland Cement Ltd
NSE:APCL
|
IN |
|
B
|
BioMaxima SA
WSE:BMX
|
PL |
|
Jilin Jian Yisheng Pharmaceutical Co Ltd
SZSE:002566
|
CN |
|
L'Occitane International SA
HKEX:973
|
LU |
|
Zhongtai Futures Co Ltd
HKEX:1461
|
CN |
|
A
|
AIZO Group Bhd
KLSE:AIZO
|
MY |
|
MGM China Holdings Ltd
HKEX:2282
|
MO |
|
D
|
Digia Oyj
OMXH:DIGIA
|
FI |
|
C
|
Chemfab Alkalis Ltd
NSE:CHEMFAB
|
IN |
|
E
|
Epoxy Base Electronic Material Corp Ltd
SSE:603002
|
CN |
|
A
|
Alliance Laundry Holdings Inc
NYSE:ALH
|
US |
Balance Sheet
Balance Sheet Decomposition
CTI Biopharma Corp
CTI Biopharma Corp
Balance Sheet Decomposition is not available for
CTI Biopharma Corp
CTI Biopharma Corp
Balance Sheet
CTI Biopharma Corp
CTI Biopharma Corp
Currency: USD
| Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
72
|
71
|
128
|
44
|
27
|
36
|
31
|
40
|
65
|
30
|
|
| Cash Equivalents |
72
|
71
|
128
|
44
|
27
|
36
|
31
|
40
|
65
|
30
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
0
|
31
|
3
|
12
|
0
|
50
|
|
| Total Receivables |
0
|
2
|
0
|
8
|
1
|
14
|
0
|
0
|
0
|
15
|
|
| Accounts Receivables |
0
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
15
|
|
| Other Receivables |
0
|
0
|
0
|
8
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
5
|
4
|
3
|
2
|
1
|
0
|
0
|
0
|
0
|
1
|
|
| Other Current Assets |
4
|
3
|
4
|
2
|
18
|
2
|
2
|
2
|
3
|
3
|
|
| Total Current Assets |
81
|
81
|
135
|
56
|
47
|
83
|
36
|
54
|
68
|
99
|
|
| PP&E Net |
6
|
5
|
4
|
3
|
2
|
2
|
5
|
3
|
3
|
2
|
|
| PP&E Gross |
6
|
5
|
0
|
3
|
2
|
2
|
5
|
3
|
3
|
2
|
|
| Accumulated Depreciation |
11
|
12
|
0
|
9
|
8
|
8
|
7
|
5
|
6
|
2
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
23
|
|
| Other Long-Term Assets |
8
|
7
|
6
|
5
|
6
|
6
|
6
|
1
|
1
|
1
|
|
| Total Assets |
94
N/A
|
92
-1%
|
144
+56%
|
64
-56%
|
55
-14%
|
90
+64%
|
46
-48%
|
58
+26%
|
72
+24%
|
126
+74%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
5
|
6
|
11
|
7
|
3
|
5
|
0
|
2
|
4
|
2
|
|
| Accrued Liabilities |
10
|
20
|
22
|
25
|
14
|
13
|
14
|
9
|
14
|
30
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
3
|
9
|
37
|
8
|
0
|
5
|
5
|
5
|
47
|
48
|
|
| Other Current Liabilities |
2
|
1
|
2
|
1
|
2
|
1
|
0
|
2
|
2
|
1
|
|
| Total Current Liabilities |
20
|
36
|
72
|
41
|
19
|
23
|
19
|
17
|
67
|
81
|
|
| Long-Term Debt |
10
|
8
|
19
|
11
|
14
|
9
|
5
|
0
|
0
|
61
|
|
| Minority Interest |
2
|
3
|
5
|
6
|
6
|
6
|
6
|
0
|
0
|
0
|
|
| Other Liabilities |
21
|
9
|
5
|
4
|
6
|
5
|
5
|
1
|
2
|
1
|
|
| Total Liabilities |
49
N/A
|
51
+4%
|
92
+83%
|
51
-45%
|
33
-34%
|
31
-6%
|
23
-27%
|
18
-19%
|
69
+277%
|
144
+109%
|
|
| Equity | |||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
1 880
|
1 976
|
2 098
|
2 150
|
2 195
|
2 225
|
2 264
|
2 328
|
2 426
|
2 519
|
|
| Additional Paid In Capital |
1 933
|
2 024
|
2 157
|
2 170
|
2 222
|
2 294
|
2 299
|
2 368
|
2 430
|
2 501
|
|
| Unrealized Security Profit/Loss |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
8
|
6
|
6
|
7
|
6
|
11
|
12
|
0
|
0
|
0
|
|
| Total Equity |
45
N/A
|
42
-8%
|
52
+24%
|
13
-74%
|
22
+64%
|
59
+169%
|
24
-60%
|
40
+69%
|
4
-91%
|
18
N/A
|
|
| Total Liabilities & Equity |
94
N/A
|
92
-1%
|
144
+56%
|
64
-56%
|
55
-14%
|
90
+64%
|
46
-48%
|
58
+26%
|
72
+24%
|
126
+74%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
15
|
18
|
28
|
28
|
43
|
58
|
58
|
76
|
100
|
131
|
|
| Preferred Shares Outstanding |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Switch to:
Switch to:
See Also
Discover More
